HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Busby, W. H. Articles by Clemmons, D. R. Search for Related Content PubMed PubMed Citation Articles by Busby, W. H., Jr Articles by Clemmons, D. R. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 263, Issue 28, 14203-14210, Oct, 1988

Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid. Isolation of two forms with different biologic actions

WH Busby Jr, DG Klapper and DR Clemmons
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill 27514.

Human amniotic fluid has been shown to contain a protein that binds insulin-like growth factor I and II (IGF-I and IGF-II). Partially purified preparations of this protein have been reported to inhibit the biologic actions of the IGFs. In these studies our laboratory has used a modified purification procedure to obtain a homogeneous preparation of this protein as determined by polyacrylamide gel electrophoresis and amino acid sequence analysis. During purification the ion exchange chromatography step resulted in two peaks of material with IGF binding activity termed peaks B and C. Each peak was purified separately to homogeneity. Both peaks were estimated to be 31,000 daltons by polyacrylamide gel electrophoresis and their amino acid compositions were nearly identical. Amino acid sequence analysis showed that both peaks had identical N-terminal sequences through the first 28 residues. Neither protein had detectable carbohydrate side chains and each had a similar affinity for radiolabeled IGF-I (1.7-2.2 x 10(10) liters/mol). In contrast, these two forms had marked differences in bioactivity. Concentrations of peak C material between 2 and 20 ng/ml inhibited IGF- I stimulation of [3H]thymidine incorporation into smooth muscle cell DNA. In contrast, when peak B (100 ng/ml) was incubated with IGF-I there was a 4.4-fold enhancement of stimulation of DNA synthesis. Additionally, pure peak B was shown to adhere to cell surfaces, whereas peak C was not adherent. The non-adherent peak C inhibited IGF-I binding to its receptor and to adherent peak B. We conclude that human amniotic fluid contains two forms of IGF binding protein that have very similar physiochemical characteristics but markedly different biologic actions. Since both have similar if not identical amino acid compositions, N-terminal sequences, and do not contain carbohydrate, we conclude that they differ in some other as yet undefined post- translational modification.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M Shimizu, J T Dickey, H Fukada, and W W Dickhoff Salmon serum 22 kDa insulin-like growth factor-binding protein (IGFBP) is IGFBP-1 J. Endocrinol., January 1, 2005; 184(1): 267 - 276. [Abstract] [Full Text] [PDF]

				S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF]

				D. R. Clemmons Use of Mutagenesis to Probe IGF-Binding Protein Structure/Function Relationships Endocr. Rev., December 1, 2001; 22(6): 800 - 817. [Abstract] [Full Text] [PDF]

				M. Westwood, J. D. Aplin, I. A. Collinge, A. Gill, A. White, and J. M. Gibson alpha 2-Macroglobulin: a New Component in the Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-1 Axis J. Biol. Chem., November 2, 2001; 276(45): 41668 - 41674. [Abstract] [Full Text] [PDF]

				K. Sakai, A. J. D'Ercole, L. J. Murphy, and D. R. Clemmons Physiological Differences in Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Phosphorylation in IGFBP-1 Transgenic Mice Diabetes, January 1, 2001; 50(1): 32 - 38. [Abstract] [Full Text]

				R. C. Baxter Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E967 - E976. [Abstract] [Full Text] [PDF]

				L. A. Bach, R. Dean, S. Youssef, and M. E. Cooper Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy Nephrol. Dial. Transplant., March 1, 2000; 15(3): 347 - 354. [Abstract] [Full Text] [PDF]

				H. Hirano, M. B. S. Lopes, E. R. Laws Jr., T. Asakura, M. Goto, J. E. Carpenter, L. R. Karns, and S. R. VandenBerg Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas Neuro-oncol, April 1, 1999; 1(2): 109 - 119. [Abstract] [PDF]

				C. Rees, D. R. Clemmons, G. D. Horvitz, J. B. Clarke, and W. H. Busby A Protease-Resistant Form of Insulin-Like Growth Factor (IGF) Binding Protein 4 Inhibits IGF-1 Actions Endocrinology, October 1, 1998; 139(10): 4182 - 4188. [Abstract] [Full Text] [PDF]

				B. Zheng, J. B. Clarke, W. H. Busby, C. Duan, and D. R. Clemmons Insulin-Like Growth Factor-Binding Protein-5 Is Cleaved by Physiological Concentrations of Thrombin Endocrinology, April 1, 1998; 139(4): 1708 - 1714. [Abstract] [Full Text] [PDF]

				S. M. Firth, U. Ganeshprasad, and R. C. Baxter Structural Determinants of Ligand and Cell Surface Binding of Insulin-like Growth Factor-binding Protein-3 J. Biol. Chem., January 30, 1998; 273(5): 2631 - 2638. [Abstract] [Full Text] [PDF]

				A. M. Mirza, S. Ezzat, and A. A. Axelrad Insulin-Like Growth Factor Binding Protein-1 Is Elevated in Patients With Polycythemia Vera and Stimulates Erythroid Burst Formation In Vitro Blood, March 15, 1997; 89(6): 1862 - 1869. [Abstract] [Full Text] [PDF]

				M. Westwood, J M. Gibson, and A. White Purification and Characterization of the Insulin-Like Growth Factor-Binding Protein-1 Phosphoform Found in Normal Plasma Endocrinology, March 1, 1997; 138(3): 1130 - 1136. [Abstract] [Full Text] [PDF]

				A. Parker, J. B. Clarke, W. H. Busby Jr., and D. R. Clemmons Identification of the Extracellular Matrix Binding Sites for Insulin-like Growth Factor-binding Protein 5 J. Biol. Chem., June 7, 1996; 271(23): 13523 - 13529. [Abstract] [Full Text] [PDF]

				T. Arai, J. Clarke, A. Parker, W. Busby Jr., T. Nam, and D. R. Clemmons Substitution of Specific Amino Acids in Insulin-like Growth Factor (IGF) Binding Protein 5 Alters Heparin Binding and Its Change in Affinity for IGF-I in Response to Heparin J. Biol. Chem., March 15, 1996; 271(11): 6099 - 6106. [Abstract] [Full Text] [PDF]

				A. Gockerman and D. R. Clemmons Porcine Aortic Smooth Muscle Cells Secrete a Serine Protease for Insulin-like Growth Factor Binding Protein-2 Circ. Res., April 1, 1995; 76(4): 514 - 521. [Abstract] [Full Text]

				K. Sakai, W. H. Busby Jr., J. B. Clarke, and D. R. Clemmons Tissue Transglutaminase Facilitates the Polymerization of Insulin-like Growth Factor-binding Protein-1 (IGFBP-1) and Leads to Loss of IGFBP-1's Ability to Inhibit Insulin-like Growth Factor-I-stimulated Protein Synthesis J. Biol. Chem., March 16, 2001; 276(12): 8740 - 8745. [Abstract] [Full Text] [PDF]